An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,323 | -40,956 | -29,114 | -17,775 | -7,655 |
| Depreciation Amortization | -435 | -692 | -317 | -72 | 1 |
| Accounts payable and accrued liabilities | 1,423 | 2,497 | 1,816 | 1,987 | 1,546 |
| Other Working Capital | 2,075 | 3,718 | 631 | -218 | 445 |
| Other Operating Activity | 664 | 1,971 | 1,160 | -259 | -1,079 |
| Operating Cash Flow | $-11,596 | $-33,462 | $-25,824 | $-16,337 | $-6,742 |
| Cash Flows From Investing Activities | |||||
| Purchase Of Investment | -14,013 | -93,836 | -76,391 | -53,984 | -998 |
| Sale Of Investment | 24,900 | 72,065 | 48,565 | 28,475 | 14,975 |
| Investing Cash Flow | $10,887 | $-21,771 | $-27,826 | $-25,509 | $13,977 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 199 | 70,366 | 70,366 | 70,365 | 63,198 |
| Common Stock Repurchased | N/A | -11 | -11 | N/A | -11 |
| Financing Cash Flow | $199 | $70,355 | $70,355 | $70,365 | $63,187 |
| Beginning Cash Position | 27,219 | 12,097 | 12,097 | 12,097 | 12,097 |
| End Cash Position | 26,709 | 27,219 | 28,802 | 40,616 | 82,519 |
| Net Cash Flow | $-510 | $15,122 | $16,705 | $28,519 | $70,422 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,596 | -33,462 | -25,824 | -16,337 | -6,742 |
| Free Cash Flow | -11,596 | -33,462 | -25,824 | -16,337 | -6,742 |